Vontobel Holding
ALGS icon

Vontobel Holding’s Aligos Therapeutics ALGS Stock Holding History

Vontobel Holding’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-500
Closed -$12.3K – 1072
2024
Q1 		$12.3K Buy
+500
New +$9.96K ﹤0.01% 1081

Other funds holding ALGS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Vontobel Holding's ALGS Position: Q2 2024 in Review

Vontobel Holding sold out of Aligos Therapeutics (ALGS) in Q2 2024, closing a stake of 500 shares — an estimated $12.3K sold.

Vontobel Holding first reported a position in ALGS in Q1 2024 and held it in 1 quarter. The position peaked at $12.3K in Q1 2024. 48 funds tracked by Wall St. Rank hold ALGS as of Q2 2024.

  • Vontobel Holding reported no remaining Aligos Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Vontobel Holding sold 500 Aligos Therapeutics shares in Q2 2024, an estimated $12.3K.
  • Vontobel Holding first reported a position in Aligos Therapeutics in Q1 2024 and held it in 1 quarter.
  • Vontobel Holding's Aligos Therapeutics position peaked at $12.3K in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2024.

Based on Vontobel Holding's 13F filing for Q2 2024, filed 13 Aug 2024.